SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS

August 11, 2022

SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS

SOMERSET, NJ — Solco Healthcare announces its FDA approval and availability of Tadalafil tablets, 2.5mg, 5mg, 10mg and 20mg, which are AB-rated generics equivalent to Cialis® and Adcirca® by Eli Lily.

Tadalafil 2.5mg, 5mg, 10mg and 20mg tablets are indicated for the treatment of erectile dysfunction (ED) and Benign Prostatic Hyperplasia (BPH), while Tadalafil 20mg tablet is used to treat pulmonary arterial hypertension (PAH, high blood pressure in your lungs) to improve exercise ability. “We are proud to be able to provide an affordable alternative to the millions of men suffering from ED and BPH and for patients suffering from PAH in America”, said Hai Wang, President of Solco Healthcare. According to IQVIA, total market sales for generic Tadalafil tablets for the last twelve months ending July 2022 were $61.1 million.

Solco Healthcare will market Tadalafil 2.5mg, 5mg, 10mg and 20mg tablets (for ED) in 30 count bottles and Tadalafil 20mg tablet (for PAH) in 60 count bottles. Please contact your Solco Healthcare National Accounts Director or customer service at (855) 581-9688 for more information.